Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=24588774
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Postoperative statin use and risk of biochemical recurrence following radical
prostatectomy: results from the Shared Equal Access Regional Cancer Hospital
(SEARCH) database
#MMPMID24588774
Allott EH
; Howard LE
; Cooperberg MR
; Kane CJ
; Aronson WJ
; Terris MK
; Amling CL
; Freedland SJ
BJU Int
2014[Nov]; 114
(5
): 661-6
PMID24588774
show ga
OBJECTIVE: To investigate the effect of statin use after radical prostatectomy
(RP) on biochemical recurrence (BCR) in patients with prostate cancer who never
received statins before RP. PATIENTS AND METHODS: We conducted a retrospective
analysis of 1146 RP patients within the Shared Equal Access Regional Cancer
Hospital (SEARCH) database. Multivariable Cox proportional hazards analyses were
used to examine differences in risk of BCR between post-RP statin users vs
nonusers. To account for varying start dates and duration of statin use during
follow-up, post-RP statin use was treated as a time-dependent variable. In a
secondary analysis, models were stratified by race to examine the association of
post-RP statin use with BCR among black and non-black men. RESULTS: After
adjusting for clinical and pathological characteristics, post-RP statin use was
significantly associated with 36% reduced risk of BCR (hazard ratio [HR] 0.64,
95% confidence interval [CI] 0.47-0.87; P = 0.004). Post-RP statin use remained
associated with reduced risk of BCR after adjusting for preoperative serum
cholesterol levels. In secondary analysis, after stratification by race, this
protective association was significant in non-black (HR 0.49, 95% CI 0.32-0.75; P
= 0.001) but not black men (HR 0.82, 95% CI 0.53-1.28; P = 0.384). CONCLUSION: In
this retrospective cohort of men undergoing RP, post-RP statin use was
significantly associated with reduced risk of BCR. Whether the association
between post-RP statin use and BCR differs by race requires further study. Given
these findings, coupled with other studies suggesting that statins may reduce
risk of advanced prostate cancer, randomised controlled trials are warranted to
formally test the hypothesis that statins slow prostate cancer progression.
|Aged
[MESH]
|Databases, Factual
[MESH]
|Humans
[MESH]
|Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
[MESH]
|Male
[MESH]
|Middle Aged
[MESH]
|Neoplasm Recurrence, Local/*epidemiology
[MESH]
|Postoperative Period
[MESH]
|Proportional Hazards Models
[MESH]
|Prostatectomy/*statistics & numerical data
[MESH]
free
free
free
